✦ LIBER ✦

Update on the cardiovascular safety of ustekinumab in pooled phase II and III psoriasis clinical trials with up to 4 years of follow-up

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Infection rates in the ustekinumab psori

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Malignancy rates in the ustekinumab psor

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

The ustekinumab safety experience in pat

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Long-term safety experience of ustekinum

✍ Kenneth B. Gordon; Kim A. Papp; Richard G. Langley; Vincent Ho; Alexa B. Kimball 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 422 KB

Cardiovascular safety of ustekinumab in

✍ K. Reich; R.G. Langley; M. Lebwohl; P. Szapary; C. Guzzo; N. Yeilding; S. Li; M- 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB

Long-term safety experience of ustekinum

✍ Mark Lebwohl; Craig Leonardi; Christopher E.M. Griffiths; Jörg C. Prinz; Philipp 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 243 KB